(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 August 2007 (30.08.2007)

PCT

(10) International Publication Number
WO 2007/096149 A1

(51) International Patent Classification:
C07K 16/24 (2006.01) *C12N 15/13* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/EP2007/001506

(22) International Filing Date:
21 February 2007 (21.02.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0603683.4 23 February 2006 (23.02.2006) GB

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Viennaa (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BARDROFF, Michael** [DE/DE]; Schietweg 2a, 81375 Munchen (DE). **EDWARDS, Matthew** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex, RH12 5AB (GB). **TUR, Mehmet** [TR/DE]; Am Steinberg 43, 52353 Duren (DE). **RATSCH, Olaf** [DE/DE]; Lochhamer Str. 79, 82166 Grafelfing (DE).

(74) Agent: **LEON, Susanna**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** THYMIC STROMAL LYMPHO PO I ET IN (TSLP) ANTIBODIES AND USES THEREOF

(57) **Abstract:** The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti- hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

WO 2007/096149 A1